PTC THERAPEUTICS, INC. 8-K

What Happened
PTC Therapeutics, Inc. (PTCT) filed a Form 8‑K on January 12, 2026 announcing preliminary, unaudited financial results for the year ended December 31, 2025 and issuing financial guidance for full‑year 2026. The company said final audited results are subject to completion of its year‑end audit. PTC presented these results and its 2026 outlook at the J.P. Morgan Healthcare Conference on January 12, 2026 (webcast), and then will enter an investor quiet period.

Key Details

• Preliminary (unaudited) FY‑2025 results: total net product and royalty revenue ≈ $823.4 million.
• Preliminary (unaudited) FY‑2025 net product revenue ≈ $587.8 million; Sephience™ (sepiapterin) net product revenue ≈ $112.1 million.
• FY‑2026 guidance: total product revenue $700M–$800M (excludes Evrysdi® royalty and collaboration revenue).
• FY‑2026 expense guidance: GAAP R&D + SG&A $775M–$815M; non‑GAAP R&D + SG&A $680M–$720M (excludes estimated non‑cash stock‑based comp of $95M).

Why It Matters
These preliminary results give investors a first look at PTC’s 2025 revenue mix and scale, including early traction for Sephience. The 2026 revenue range and expense guidance provide a framework for expectations on growth and spending next year—important for modeling profitability, cash needs, and cadence of program investments. Remember these 2025 figures are unaudited and the company will finalize results after its year‑end audit.